2007 BIO International Convention, the Global Event for Biotechnology, takes place May 06 - 09, 2007 at the Boston Convention & Exhibition Center. For in-depth information about the event, visit http://www.bio2007.org/Media/releases.html.
Below are profiles from BIO exhibitors, listed D through M.
Business Wire is the official news wire for 2007 BIO International Convention. Breaking news releases and photos are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource as well as the official show site.
Company: | D-Pharm Ltd |
Media Contact: | thorovitz@dpharm.com |
Phone: | 97289385100 |
E-mail: | thorovitz@dpharm.com |
Web: | www.dpharm.com |
D-Pharm Ltd is a clinical stage company focused on discovery and development of lipid-based therapeutics for CNS disorders and cancer. D-Pharm's most advance product, DP-b99, recently successfully completed a Phase IIb study in acute stroke patients. DP-b99 was found to double the chance to fully recover following stroke. These results will be described by D-Pharm's President and CEO at the Bio 2007 Business Forum in Boston on Wednesday May 9th, Room A at 9.00am. | |
 | |
D-Pharm's other pipeline products include DP-VPA (Phase II) for epilepsy, migraine and bipolar disorder and DP-460 (preclinical) for Alzheimer's disease. Visit www.dpharm.com. | |
 | |
 | |
Company: | Dry Ice Corp. |
Booth: | 600 |
Media Contact: | Pat Walsh |
Phone: | 410-536-4939 |
E-mail: | dpipat@msn.com |
Web: | www.dryicecorp.com |
Dry Ice Corp. is the largest regional supplier of dry ice products and customized delivery services in the Northeastern U.S. We specialize in supplying the Biotech, Pharmaceutical, and Research industries with a reliable supply of "fresh" dry ice and on-site "desk-top" delivery services. | |
 | |
From Maine to Virginia, you can count on Dry Ice Corp. to provide uninterrupted supply of essential dry ice from one of our six branches located in; Boston, MA-Branford, CT- Newark, NJ-New York City, NY-Philadelphia, PA and Baltimore, MD. | |
 | |
Visit our web-site at www.dryicecorp.com to learn more about our Total Dry Ice Supply Programs. | |
 | |
 | |
Company: | DSM Pharmaceutical Products |
Booth: | 3021 |
Media Contact: | Terry Novak |
Phone: | 973-257-8471 |
E-mail: | Terry.novak@dsm.com |
Web: | http://www.dsmpharmaceuticals.com |
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products. | |
 | |
From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers' unique manufacturing needs. | |
 | |
 | |
Company: | Dynogen Pharmaceuticals, Inc. |
Media Contact: | Heather Savelle |
Phone: | 781.839.5149 |
E-mail: | hsavelle@dynogen.com |
Web: | www.dynogen.com |
Dynogen is a clinical-stage company developing a portfolio of treatments for gastrointestinal and genitourinary disorders. The Company is focused on attractive and untapped markets in disease areas that severely impair a patient's quality of life, such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD) and overactive bladder (OAB). Dynogen leverages its development expertise to identify promising clinical compounds and rapidly advance them towards registration. | |
 | |
Dynogen currently has three clinical stage products in various stages of development for five indications: | |
"¢DDP733 for IBS with constipation (IBS-c) and NGERD | |
"¢DDP225 IBS with diarrhea (IBS-d) and OAB | |
"¢DDP200 for OAB | |
 | |
 | |
Company: | Economic Development Board, Singapore |
Booth: | 2533 |
Media Contact: | Sheo Shanker Rai |
Phone: | 65 6395 7784 |
E-mail: | sheo_shanker_rai@bmsg.gov.sg |
Web: | www.biomed-singapore.com |
The Economic Development Board is Singapore's lead agency responsible for planning and executing strategies to sustain Singapore's position as a compelling global hub for business and investment. The Biomedical Sciences Group oversees the development of Singapore's biomedical sciences industry and supports biomedical sciences companies with manufacturing, research and development, headquarter and other high-value operations in Singapore. www.biomed-singapore.com | |
 | |
 | |
Company: | Economic Development San Marcos |
Booth: | 3065 |
Media Contact: | Kim Moore |
Phone: | 512-393-3400 |
E-mail: | kmoore@ecodevsanmarcos.org |
Web: | www.ecodevsanmarcos.org |
Economic Development San Marcos (EDSM) is a division of Global Marketeer Group, Inc. under contract with the City of San Marcos, Texas. EDSM serves as a catalyst for job creation, job retention and business investment. San Marcos is located between Austin and San Antonio on Interstate Highway 35 providing interstate and international travel. Location, infrastructure, and market access make San Marcos a successful community for business and industry. Texas State University-San Marcos is the largest university of the Texas State University System with over 27,500 students. Texas State provides a well-trained workforce for the region's growing high tech industry. | |
 | |
 | |
Company: | EBD Group |
Booth: | 1059 |
Media Contact: | Constantine Theodoropulos |
Phone: | 617-619-9801 |
E-mail: | ctheodoropulos@ebdgroup.com |
Web: | www.ebdgroup.com |
EBD Group is the leading partnering firm for the global biotechnology industry. Since 1993, firms in the life sciences have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships that drive their business. | |
 | |
EBD Group's conferences (run in collaboration with leading industry partners and international trade associations such as BIO and Eucomed) include BIO-Europe, BIO-Europe Spring, BioEquity Europe (co-organized with BioCentury Publications); and the medical technology and BioDevice Partnering. EBD's novel web-based partnering software system is also used at numerous third-party events around the world. Outside of the conference format, EBD Group's consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies. | |
 | |
 | |
Company: | Eden Biodesign |
Booth: | 3225 |
Media Contact: | Stéphanie Monfront |
Phone: | 0207 861 3838 |
E-mail: | s.monfront@defacto.com |
Web: | www.edenbiodesign.co.uk |
Eden Biodesign is a world leader in the provision of biopharmaceutical development and manufacturing expertise and now operates the new world class UK National Biomanufacturing Centre. | |
 | |
The combination of the advanced facility and the expertise found in its people, mean Eden Biodesign has the scope and the capacity to handle over 95% of the products and processes found within the biopharmaceutical pipeline. | |
--Recombinant protein therapies (antibodies and fragments) | |
--Natural proteins | |
--Gene therapies | |
--Cell therapies | |
--Vaccines (VLP, Cancer vaccines, whole cell vaccines) | |
--Tissue engineering | |
 | |
 | |
Company: | Embera NeuroTherapeutics, Inc. |
Booth: | 1725 - Louisiana Pavilion |
Media Contact: | Stephanie Martin |
Phone: | (318) 213-0198 |
E-mail: | stephanie@emberaneuro.com |
Web: | www.emberaneuro.com |
Embera NeuroTherapeutics is a specialty pharmaceutical company dedicated to developing and commercializing novel treatments for a broad range of addictions and neuropsychiatric disorders. Embera is preparing to enter clinical trials for EMB-001, a patent-pending drug combination developed for the treatment of addiction and psychiatric disorders. EMB-001 targets the specific neurological pathways associated with craving and relapse and may be effective in treating a wide array of addictions including cocaine, methamphetamine, and alcohol dependence as well as psychiatric illnesses such as anxiety and compulsive behavioral disorders. For additional information regarding EMB-001 and Embera NeuroTherapeutics please visit the company's website: http://www.emberaneuro.com. | |
 | |
 | |
Company: | EMC Corporation |
Booth: | Booth #533, Pod #A3 |
Ticker Symbol & Exchange: | EMC, NYSE |
Media Contact: | Hadley Weinzierl |
Phone: | 508 293 7642 |
E-mail: | Weinzierl_hadley@emc.com |
Web: | www.emc.com |
EMC Corporation is the world's leading developer and provider of information infrastructure technology and solutions that enable life sciences organizations of all sizes---from pharmaceutical, biotechnology, and medical device, academic research labs, to government organizations --- to transform the way they create value from their information. | |
 | |
EMC representatives will discuss and demonstrate how life sciences organizations can store information more intelligently, leverage content for collaboration and compliance, protect information effectively and affordably, and secure critical assets. EMC will also discuss its information archiving and compliance solutions for emerging and enterprise life sciences organizations. | |
 | |
 | |
Company: | Empyrean Management Group |
Booth: | 2700 |
Media Contact: | Kristy Boldt |
Phone: | 610-275-4400 |
E-mail: | kboldt@HireSmartPeople.com |
Web: | www.HireSmartPeople.com |
Empyrean Management Group, Inc. (EMG) is a Management Consulting company focused on the most important aspect of any organization, its people. EMG provides Fixed Price/Fixed Time outsourced HR, Recruiting, and Training services on a national basis for clients ranging from Fortune 50 companies to emerging and midsize businesses spanning across many industries. EMG facilitates the design and implementation of systems that attract and retain the best possible employees for our clients. | |
 | |
Inc. Magazine and the Philadelphia Business Journal have recently recognized EMG as one of the fastest growing privately held companies in the US and Philadelphia, PA regions. | |
 | |
 | |
Company: | Enterprise Honolulu (Economic Development, Hawaii) |
Booth: | 687 |
Media Contact: | Mark Ritchie |
Phone: | (808) 521-3611 x11 |
E-mail: | mritchie@enterprisehonolulu.com |
Web: | http://www.enterprisehonolulu.com |
Enterprise Honolulu is a private sector economic development organization. We assist life science and other technology companies to grow in Hawaii and to develop global markets. Working with our partner organizations we offer Hawaii companies a range of services, including business planning, financing and business development and expansion assistance. Also, we assist mainland and international companies exploring investment locations for life science projects. Our organization can provide site selectors a wealth of information on Hawaii's competitive advantages as well as coordinate a range of additional services to companies establishing operations in Hawaii. | |
 | |
 | |
Company: | ERA Consulting Group |
Booth: | 774 & 1864 |
Media Contact: | Mr. Paul Cronin |
Phone: | 44-20-7510-0200 |
E-mail: | info@eraconsulting.com |
Web: | www.eraconsulting.com |
The ERA Consulting Group provides regulatory affairs and product development consulting services, specializing in strategies for biotech and other biological products. We have offices in Germany (near Hannover), UK (London), USA (Washington D.C.) and Australia (Brisbane). Our experience covers over 250 products with input ranging from feasibility studies and advice on regulatory strategy, to the compilation and submission of complete dossiers. Our clients range from virtual biotech companies to the largest pharmaceutical corporations. Our 20-year track record places us in an unrivalled position in this specialized field and provides a level of expertise from which all clients can benefit. | |
 | |
 | |
Company: | EuropaBio |
Booth: | 781 |
Media Contact: | Adeline Farrelly, Communications Director |
Phone: | 32 2 735 0313 |
E-mail: | a.farrelly@europabio.org |
Web: | www.europabio.org |
EuropaBio's mission is to promote an innovative and dynamic biotechnology-based industry in Europe. | |
 | |
EuropaBio (the European Association for Bioindustries) has 78 direct members operating Worldwide, 12 associate members and 5 bioregions as well as 25 national biotechnology associations representing some 1800 small and medium sized enterprises involved in research and development, testing, manufacturing and distribution of biotechnology products. | |
 | |
 | |
Company: | European Pavilion |
Booth: | 773 |
Media Contact: | Stephane Hogan |
Phone: | 32 2 296 2965 |
E-mail: | stephane.hogan@ec.europa.eu |
Web: | www.ec.europa.eu/research/eu-bio2007 |
The EU Joint Delegation at BIO 2007 consists of experts and high level policy makers from the European Commission, the executive arm of the EU, the European Patent Office (EPO) and the European Medicines Agency (EMEA). Through its participation in the BIO International Convention, the EU Joint Delegation will present current developments in biotech in the EU relevant for the global industry: policy, regulation, scientific cooperation and funding. It will be headed by Mr. John Bruton, the European Union Ambassador to the USA. The EU Pavilion (booth number 773) features representatives of the EC, EMEA and EPO. | |
 | |
 | |
Company: | Evotec |
Booth: | UK Pavillion - Booth 1660 & German Pavillion - Booth 555 |
Ticker Symbol & Exchange: | EVT |
Media Contact: | Sarah Herrmann |
Phone: | 0207 867 3838 |
E-mail: | s.herrmann@defacto.com |
Web: | www.evotec.com |
Evotec AG (FSE: EVT) is a leader in the discovery and development of novel small molecule drugs. The Company has built a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is building a pipeline of drug candidates for partnering. | |
 | |
Through its collaborations and proprietary projects Evotec is providing the highest quality research results to its partners: | |
 | |
--In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. | |
 | |
--In collaborations, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. | |
 | |
 | |
Company: | Favrille, Inc. |
Ticker Symbol & Exchange: | Nasdaq: FVRL |
Media Contact: | Pete De Spain |
Phone: | (858) 526-2426 |
E-mail: | pdespain@favrille.com |
Web: | www.favrille.com |
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. | |
 | |
 | |
Company: | FLAMMA Sas |
Booth: | 2025 - Italy Pavilion |
Phone: | 33 1 55 52 14 50 |
E-mail: | Fabrice.cornille@flamma.fr |
Web: | www.flamma.it |
FLAMMA is a manufacturer founded in 1950 and based in Bergamo/Italy with specific expertise in the field of AA derivatives & related compounds. Company expertise ranges from the production of AA derivatives classified as starting materials/key intermediates, to the related compounds classified as active pharmaceutical ingredients. | |
 | |
Currently FLAMMA operates also in France with the marketing subsidiary Flamma sas and in P.R. China with the manufacturing joint-venture Flamma Gongan Biochemicals Co. Ltd for the production of some basic amino-acids and with a fully owned Research & Technology Center in Shanghai, Shanghai Flamma Bioscience Co. Ltd. | |
 | |
 | |
Company: | Florida Biologix |
Booth: | 1743 Florida Pavillion |
Media Contact: | Jim Ayala- Director of Business Development |
Phone: | 386-418-8199 ext 203 |
E-mail: | jayala@floridabiologix.ufl.com |
Web: | www.floridabiologix.ufl.com |
Florida Biologix is non-profit Contract Manufacturing Organization (CMO) that offers a wide range of biopharmaceutical development and manufacturing services to the biotechnology industry and to biomedical research institutions, including: cell line engineering, cGMP cell banking, upstream and downstream processes design, process and assay development, cGMP production of proteins expressed in mammalian cells (including monoclonal antibodies, recombinant proteins, enzymes, vaccines, and other biomolecules), purification, aseptic filling (including small molecules, nucleic acids, and proteins), product testing, and regulatory support. Products made in this facility are suitable for pre-clinical, and Phase I and II human clinical trails. | |
 | |
 | |
Company: | Florida High Tech Corridor Council |
Booth: | 1743 |
Media Contact: | Justin Campfield |
Phone: | (407) 423-8006 |
E-mail: | jcampfield@thestrategicfirm.com |
Web: | www.FloridaHighTech.com |
The Florida High Tech Corridor Council (FHTCC) is an economic development initiative of the University of Central Florida, the University of South Florida and the University of Florida whose mission is to attract, retain and grow high tech industry in the 23-county Corridor. | |
 | |
A partnership of more than 20 local and regional economic development organizations (EDOs) and 14 community colleges, FHTCC employs a strategic approach to high tech economic development that involves matching funds research, workforce development and a marketing program leveraging governmental, EDO and corporate budgets on a regional rather than local basis. | |
 | |
 | |
Company: | Foamix Ltd. |
Booth: | 3171 |
Media Contact: | Dov Tamarkin |
Phone: | 972-8-9316233 |
E-mail: | dov@foamix.co.il |
Web: | www.foamix.co.il |
Foamix develops proprietary topical foam products for dermatology, gynecology, wound and burn care. By incorporating drugs in foam, we create premium products with improved convenience, higher compliance and better efficiency of treatment. We currently collaborate with 8 pharmaceutical companies in the development of proprietary foam drugs; and we have our in-house pipeline of dermatological and gynecological drugs in foam. | |
 | |
The Foamix foam delivery platforms include: | |
 | |
1. Oil in water emulsion foam (cream-like) | |
2. Water in oil emulsion foam (occlusive-cream-like) | |
3. Waterless hydrophilic foam (hydrophilic-ointment-like) | |
4. Oily foam (with or without water) | |
5. Petrolatum based foam (ointment-like) | |
6. Suspension foam | |
 | |
 | |
Company: | Formatech, Inc. |
Booth: | 533-D7 |
Media Contact: | Jeffrey Bernard |
Phone: | 978-725-9077 |
E-mail: | jbernard@formatech.com |
Web: | www.formatech.com |
Formatech is a dedicated contract service provider that excels delivering unique solutions to our client's product development and manufacturing challenges. | |
 | |
Our development services include preformulation & formulation development of all common dosage forms, cell culture/fermentation development and purification/downstream process optimization. | |
 | |
Developing biotherapeutic products is one of Formatech's strengths. Our accomplishments include developing Ab formulations at concentrations in excess of 200 mg/mL and an orally bioavailable peptide formulation. | |
 | |
Our aseptic manufacturing facility produces liquid & lyophilized dosage units for clinical supplies or small scale commercial products. Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and full ICH Guideline Stability Programs. | |
 | |
 | |
Company: | Fritz Gyger AG |
Booth: | 1919, Swiss Biotech Pavilion |
Media Contact: | Barbara Rohner-Gunziger |
Phone: | 41 (0)33 336 22 77 |
E-mail: | sales@fgyger.ch |
Web: | www.fgyger.ch |
Fritz Gyger AG was founded in 1959 in Switzerland. | |
 | |
Since 1992, High Speed Micro Solenoid Valves have been developed and produced, with ultra-hard materials as their key elements. The newest generation of modular SMLD valves find their application for example, in the fields of analysis technology and nano litre dispensing devices. The technology of Gyger sets new standards with reference to miniaturization, liquid metering accuracy and lifetime. | |
 | |
The development and manufacturing of functional modules for HPLC pumps makes Gyger a strong partner in this field. | |
 | |
Gyger offers a service to fulfil the need of customised solutions for micro dispensing systems. | |
 | |
 | |
Company: | Frontier BioSciences, Inc. |
Booth: | 688 |
Media Contact: | Beth Wong, AVP, Business Development |
Phone: | 240-372-2100 |
E-mail: | bwong@frontierbsi.com |
Web: | http://www.frontierbsi.com/ |
Frontier BioSciences, Inc. is a MD-based company providing preclinical CRO services in Chengdu, China. With its partner, the National Chengdu Center for Safety Evaluation of Drugs, it provides preclinical toxicology services, including PK/TK, Animal Models, General Toxicology, Developmental & Reproductive Toxicology, Safety Pharmacology, and Genetic Toxicology, supported by in-house bioanalytical, clinical pathology, and histopathology services. The state-of-the art toxicology facilities encompass 80,000 sq. ft. and are equipped with the latest advanced technology and are operated by highly-trained and experienced staff with international CRO experience. | |
 | |
 | |
Company: | Fundacion Biociencia |
Booth: | 2771 Chile Pavilion |
Media Contact: | Olivier Rickmers |
Phone: | 56 2 343 25 78 |
E-mail: | orickmer@bioscience.cl |
Web: | www.bioscience.cl |
High-Knowledge Institution specialized on Extremophiles R&D. | |
 | |
 | |
Company: | Fusion Antibodies |
Booth: | 1875 |
Media Contact: | Dr Paul Kerr |
Phone: | 4477929734619 |
E-mail: | Paul.kerr@fusionantibodies.com |
Web: | www.fusionantibodies.com |
Fusion Antibodies is a biotechnology company focused on the discovery, development and commercialisation of antibody-based therapeutics for cancer & angiogenesis. | |
 | |
Fusion also provides contract services for the rapid expression & purification of recombinant proteins, antibody sequencing and antibody engineering for the research, diagnostic and therapeutic markets. | |
 | |
 | |
Company: | Genome Prairie |
Booth: | #823 - Manitoba-Canada Pavilion |
Media Contact: | Carol Reynolds |
Phone: | (306) 241-9033 / cell (306) 668-3574 |
E-mail: | creynolds@genomeprairie.ca |
Web: | www.genomeprairie.ca |
Genome Prairie (www.genomeprairie.ca) is the leading organization for support and management of large-scale genomics and proteomics research projects in Manitoba and Saskatchewan, Canada. With its partners, Genome Prairie has supported more than $120 million of research activity in plant, animal and human genomics, bioinformatics, instrumentation development and bioethics since 2000. | |
 | |
Current research projects led by Genome Prairie include the North American Conditional Mouse Mutagenesis (NorCOMM) Project (www.norcomm.org) and the Crop Adaptation Genomics Project (www.cropadaptationgenomics.ca) involving frost-tolerant wheat. | |
 | |
Genome Prairie works collaboratively with all levels of government, universities and industry provincially, nationally and internationally to advance genomics and proteomics research. | |
 | |
 | |
Company: | genOway |
Booth: | French pavilion-1207 |
Phone: | 33 437 65 41 00 |
E-mail: | info@genoway.com |
Web: | www.genOway.com |
Operating in Europe, North America and Asia, genOway proposes time saving and cost effective strategies for in vivo drug development programs. Focusing its effort on the mouse and rat, genOway has developed a complete range of innovative technological solutions to create a new generation of customized transgenic models. genOway's expertise combines technologies classically used in transgenesis and several cutting-edge proprietary technologies aiming at enhancing the efficiency, security and relevance of the tailor-made animal model ultimately developed. | |
 | |
Moreover, genOway license policy allows his clients to have a free use of the model developed for target validation and drug discovery purposes. | |
 | |
 | |
Company: | GenScript Corporation |
Booth: | 1023 |
Phone: | 732-885-9188 |
E-mail: | info@genscript.com |
Web: | www.genscript.com |
As a pioneer of the life science research service industry, GenScript Corporation has developed, reliable and innovative techniques, rock-solid quality control, and a one-stop service package that provides quality gene, peptide, protein, and antibody products and services at competitive prices. Our services include gene synthesis, cloning and mutagenesis, protein expression and purification, antibody production, and gene functional analysis. | |
 | |
GenScript's business philosophy has always been to satisfy the customer's needs through adaptation and experience. GenScript is proud to participate in the 2007 BIO International Convention and looks forward furthering partnerships with customers, business peers, and other members of the biotechnology community. | |
 | |
 | |
Company: | GlaxoSmithKline Biopharmaceuticals |
Booth: | 1160 |
Ticker Symbol & Exchange: | GSK |
Media Contact: | Anthony J Zuazo |
Phone: | 610 239 3887 |
E-mail: | gsk.biopharm@gsk.com |
Web: | www.gsk.com/biopharm |
GSK Biopharmaceuticals is a full-service provider in the development and cGMP preparation of biopharmaceutical proteins for clinical trials and the marketplace. Our services include the low-cost, rapid scale-up and manufacture of mammalian cell derived proteins at up to 5,000L scale and the preparation of formulated bulk products. | |
 | |
 | |
Company: | GLW Storing Systems |
Booth: | 658 |
Media Contact: | Mrs. Astrid Hartenstein |
Phone: | 49 931 6677 210 |
E-mail: | info@glw-storingsystems.com |
Web: | www.glw-storingsystems.com |
GLW is a privately owned company in Northern Bavaria, specialized in sample storage systems (plastics, metal) for long-term storage, deep freezing and transportation. | |
 | |
 | |
Company: | GlycoGene, Inc. |
Booth: | 2549-Japan Pavilion |
Media Contact: | Tadayoshi Kawasaki, Ph.D., President & CEO |
Phone: | 81-(0)29-855-1080 |
E-mail: | Tadayoshi-Kawasaki@aist.go.jp |
Web: | http://www.glycogene.co.jp |
We can provide services of 1) Oligosaccharide synthesis, 2)Glycan analysis, 3)Screening of Biomarkers, 4) Glyco-engineering, and 5) Biopharmaceutical development by modifying the glycans. | |
 | |
GlycoGene, Inc., will provide services of Oligosaccharide synthesis, either N-glycan or O-glycan by use of over 180 human glycosyltransferases. Also we can provide services of glycan analysis of glycoproteins. We also are working on the Screening of Biomarkers which related to glycan, glycosyltransferases and the genes. We are interesting to have collaboration with pharmaceutical companies to develop a biopharmaceuticals with use of Glyco-engineering, either a new one or a biosimilar. | |
 | |
 | |
Company: | Glycotope GmbH |
Booth: | 565 |
Media Contact: | Dr. Hans Baumeister |
Phone: | 49-(0)30 941 084 207 |
E-mail: | Hans.baumeister@glycotope.com |
Web: | www.glycotope.com |
Glycotope - the GlycoEngineering Company - has specialized in exploring the glycosylation machinery and health related significance of sugar structures on proteins and on microorganisms. Based on GlycoExpress, a proprietary human cell-line to generate fully human glycosylated proteins with optimized sialylation degrees, we develop own glycoproteins for therapeutic use, tumor specific antibodies and vaccines, as well as nutraceuticals with specific health characteristics. Furthermore, the company offers services in form of integrated glycoengineering and antibody engineering solutions. | |
 | |
 | |
Company: | Government of Canada BioPortal |
Booth: | Booth #815 / Government of Canada Pavilion |
Media Contact: | Joshua Belinko |
Phone: | 613-954-7737 |
E-mail: | Joshua@biotech.gc.ca |
Web: | http://biotech.gc.ca |
The highly acclaimed Government of Canada BioPortal is designed for scientists, researchers, business people, consumers, regulators, and anyone interested in biotechnology. It is the definitive source for information on Canada's biotechnology regulations, investment and business opportunities, government policies and research activities, public opinion, and consultation activities on key issues. See http://biotech.gc.ca. | |
 | |
 | |
Company: | GP Pharm |
Booth: | 988 |
Media Contact: | Xavier Vergés |
Phone: | 0034936388000 |
E-mail: | xverges@gp-pharm.com |
Web: | www.gp-pharm.com |
GP Pharm is located in Barcelona (Spain). Our activities are focused on development of injectable products within Urology and Oncology fields, some based in own Drug Delivery Systems. These technological platforms include microspheres and liposomes. | |
 | |
The company works in the complete development of these drugs, from preclinical studies until the launch to the market. These specialities will be marketed either under own brands or through licenses. The new production plant of GP Pharm recently achieved EU GMP approval and started manufacturing operations, being also designed to be FDA GMP approved. | |
 | |
 | |
Company: | Greater Dallas Chamber Technology Business Council |
Media Contact: | Jo Trizila |
Phone: | 214-746-6690 |
E-mail: | jtrizila@dallaschamber.org |
Web: | www.DallasTBC.org / www.BioDFW.org |
The Greater Dallas Chamber's Technology Business Council promotes Dallas/Fort Worth as a world-class technology center and provides the region with a vehicle to effectively assemble all parties related to its technology resources and infrastructure. This objective supports the Chamber's overall mission of enabling continual business growth throughout North Texas while helping the region maintain its technology preeminence on a national scale. There are a host of issue-specific council groups, events and affiliated opportunities for participation through the Technology Business Council investment. For more information, please visit www.DallasTBC.org or contact tech@dallaschamber.org. | |
 | |
BIODFW fosters an open, entrepreneurial environment that encourages growth and innovation; develops an information clearinghouse of relevant regional resources in the life sciences; and supports regional economic development endeavors in the life science arena. BioDFW's goal is to be the primary vehicle that establishes the North Texas region as a global competitor in the life science industry and to foster an ideal climate for entrepreneurs, researchers, industry management and staff, faculty, students and related business suppliers. BIODFW offers a monthly breakfast series featuring keynote speakers focused on business issues and opportunities in the life science industry. For more information on BioDFW's initiatives, please visit www.BioDFW.org. | |
 | |
 | |
Company: | Greater Phoenix Economic Council |
Booth: | Arizona Pavilion - Booth #2255 |
Media Contact: | Linda Brady |
Phone: | 602-350-8809 |
E-mail: | lbrady@gpec.org |
Web: | www.gpec.org |
Greater Phoenix's diverse economic base, highly skilled workforce and strong business climate position us firmly among the most competitive regions in the world. | |
 | |
When you are faced with obtaining the facts you need to make the right decision on relocating or expanding your business, GPEC is your resource. | |
 | |
Our team of expansion and relocation specialists confidentially help you obtain all the facts you need to thoroughly evaluate the region. We save you countless hours of research and analysis by providing a full complement of services, all at no cost or obligation to you. | |
 | |
Contact GPEC for more information: 800.421.4732. | |
 | |
 | |
Company: | Greater Tampa Chamber of Commerce |
Booth: | 1743 (Enterprise Florida Pavilion) |
Media Contact: | Chris Smith, Vice President Public Policy |
Phone: | (813) 276-9455 |
E-mail: | csmith@tampachamber.com |
Web: | http://www.tampachamber.com/economic_development.asp |
The Greater Tampa Chamber of Commerce Committee of One Hundred (C100) is Tampa/Hillsborough County's official economic development partnership, funded by Hillsborough County, the cities of Tampa, Plant City, and Temple Terrace, and private sector investors. C100 provides confidential site selection services for life science business expansion and relocation projects. http://www.tampachamber.com/economic_development.asp | |
 | |
 | |
Company: | GTC Biotherapeutics |
Booth: | # 533 / Pod# 23 |
Ticker Symbol & Exchange: | GTCB |
Media Contact: | Thomas Newberry |
Phone: | 508-370-5374 |
E-mail: | thomas.newberry@gtc-bio.com |
Web: | www.gtc-bio.com |
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn®, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. In addition to ATryn®, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases. Additional information is available at http://www.gtc-bio.com. | |
 | |
 | |
Company: | Hawaii Life Sciences |
Booth: | 687 |
Media Contact: | Elizabeth Corbin |
Phone: | (808) 255-1560 |
E-mail: | ecorbin@dbedt.hawaii.gov |
Why Hawaii? Unique marine & terrestrial biodiversity throughout the Hawaiian islands; Outstanding capability for biofuels development; Ethnically diverse state, ideal for clinical trials; Excellent work force; Venture capital availability; Nation's most generous high technology investment and R&D tax incentives; Strategic Asia-Pacific location. | |
 | |
 | |
Company: | HealthCare Institute of New Jersey |
Booth: | New Jersey Pavilion |
Media Contact: | William Healey/EVP or Hollie Gilroy, Director of communications |
Phone: | 908-334-7229(Healey) or 908-212-0333 (Gilroy) |
E-mail: | healey@hinj.org / gilroy@hinj.org |
Web: | www.hinj.org |
The HealthCare Institute of New Jersey (HINJ) is headquartered in Bridgewater, in the heart of the Garden State's pharmaceutical and medical technology core. | |
 | |
HINJ represents 33 of the largest researched-based pharmaceutical and medical technology firms, virtually all of whom call NJ their world or North American headquarters. HINJ members employ more than 60,000 persons in the state and 100,000 indirectly in spin-off jobs. | |
 | |
 | |
Company: | Helix BioMedix, Inc. |
Ticker Symbol & Exchange: | OTCBB: HXBM |
Media Contact: | Alison Ziegler, Investor Relations |
Phone: | 212-554-5469 |
E-mail: | Alison@cameronassoc.com |
Web: | www.helixbiomedix.com |
Helix BioMedix, Inc. is a biopharmaceutical company with a vast library of diverse bioactive peptides. The company's mission is to enrich clinical practice and the patient and consumer experience by expanding opportunities to tap the health, beauty and safety benefits of advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptide technology. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care, acne treatment and other topical anti-infective pharmaceuticals and wound healing. More information may be found on the company's website at www.helixbiomedix.com. | |
 | |
 | |
Company: | HENOGEN SA |
Booth: | 2480 |
Media Contact: | Marc Gesnot |
Phone: | 32 71 34 79 00 |
E-mail: | marc.gesnot@henogen.com |
Web: | www.henogen.com |
Henogen is a multipurpose biotech facility addressing bio-manufacturing issues and has extensive knowledge in performing and/or accompanying partners through the process development and cGMP production up to phase III. | |
--cGMP BL2/BL3 facilities including fill and finish. | |
--European-wide agreement No. 1535 for manufacturing pharmaceutical products. | |
--Track records: r-proteins, subunit and live attenuated vaccines, monoclonal antibodies, viral vectors, | |
--"Elite European Company" (critical/comparative study of Biotech Companies, EuropaBio 2006). | |
 | |
Bio-manufacturing capabilities: | |
--Microbial fermentation (150L). | |
--Mammalian & Insect cell culture (80L perfusion, 300L fed batch). | |
--Virus production. | |
 | |
 | |
Company: | High Resolution Engineering |
Booth: | 3058 |
Media Contact: | Ann Bellinger |
Phone: | 781 932 1912 |
E-mail: | abellinger@hireseng.com |
Web: | www.hireseng.com |
High Resolution Engineering provides world class engineering services for the life science community. Our MicroCell is designed for unmatched reliability and features self identifying, dockable carts paired with innovative docking stations. Our multithreading, dynamic scheduling algorithm, Cellario will improve your assay scheduling timings and is easy to use. | |
 | |
 | |
Company: | HistoRx, Inc. |
Booth: | 1371 |
Media Contact: | John Tonkinson, PhD |
Phone: | 203-498-7500 x220 |
E-mail: | jtonkinson@historx.com |
Web: | www.historx.com |
HistoRx analyzes biomarkers in situ using a platform capable of measuring biomarker concentration with subcellular resolution in tissue sections and tissue microarrays. HistoRx forms partnerships with pharmaceutical companies to develop biomarker assays and companion diagnostic tests. With the results from AQUA® analysis scientists have, for the first time, highly quantitative, standardized and reproducible IHC results. HistoRx sells the PM-2000 instrument and AQUA® software, the most advanced quantitative fluorescent immunohistochemical analysis of tissue microarrays/sections available, to academic and not-for-profit research institutions for noncommercial use. With proprietary AQUA® algorithms, the guesswork is taken out of IHC. | |
 | |
 | |
Company: | Health Protection Agency |
Booth: | 1776 |
Media Contact: | Dr Phil Luton |
Phone: | 44 (0) 7887 656001 |
E-mail: | business@hpa.org.uk |
Web: | www.hpa.org.uk/business |
The UK's Health Protection Agency was formed in 2003 to provide a coordinated response to emerging chemical, radiological and biological health threats, including the threat of bioterrorism. The Agency has over 3000 staff in 3 national Centres, as well as at regional and local levels who work to "Protect People, Prevent Harm and Prepare for Threats". | |
 | |
We undertake research and development of vaccines and therapeutics against infectious diseases, including work for the US National Institute of Allergy & Infectious Diseases, as well as testing of diagnostics, the running of emergency training exercises and the manufacture a number of healthcare products. | |
 | |
 | |
Company: | Hydra Biosciences |
Media Contact: | Russell Herndon |
Phone: | 617 494 5230 |
E-mail: | rherndon@hydrabiosciences.com |
Web: | www.hydrabiosciences.com |
Hydra Biosciences is a development stage biopharmaceutical company based in Cambridge, Massachusetts. Hydra is developing novel small molecules for the treatment of pain, inflammation, cardiovascular and other diseases by focusing on a new target class: Transient Receptor Potential (TRP) ion channels. The TRP superfamily is a recent discovery and Hydra's team includes the world-leaders in electrophysiology and TRP channel biology. Hydra's two lead programs have been tested in 6 different pre-clinical pain models and have shown excellent efficacy, without the debilitating side effects that exist with current pain therapeutics. These unique programs are targeted at the $20B pain market. | |
 | |
 | |
Company: | Ichor Medical Systems, Inc. |
Media Contact: | Tom Gable, Gable PR |
Phone: | 877-251-3888 |
E-mail: | tom@gablepr.com |
Web: | www.ichorms.com |
Ichor has developed a patented one-step electroporation system that provides rapid, effective and reproducible administration of DNA drugs and vaccines with minimal operator training or skill. The integrated and fully-automated Ichor TriGrid(TM) Delivery System allows the site of injection, placement of electrodes, rate of agent administration, and timing of electroporation delivery to be controlled in a user independent fashion. As a result, Ichor's technology makes the clinical application of electroporation easy, safe, efficient, and totally compatible with the development and commercialization of DNA-based products, enhancing DNA uptake by several orders of magnitude compared to conventional methods of delivery. | |
 | |
 | |
Company: | ICON plc |
Booth: | 2923 & 2925 |
Ticker Symbol & Exchange: | ICLR on NASDAQ |
Media Contact: | Erica Hill |
Phone: | 215-616-3286 |
E-mail: | hillE@iconus.com |
Web: | www.iconclinical.com |
ICON is a full service clinical research organization providing a comprehensive range of clinical services in Phase I-IV clinical trials to the pharmaceutical, biotechnology and device industries. With 52 offices in 30 countries across the globe, ICON has the infrastructure necessary to take on global mega trials, but remains flexible enough to provide development services on a stand-alone basis or as part of an integrated "full-service" solution for locally managed projects. | |
 | |
ICON has one of the most experienced regulatory groups in the industry, with a proven track record of success in regulatory submissions and regulatory agency/authority interactions. | |
 | |
 | |
Company: | IDT |
Booth: | 1310 and 2133 |
Media Contact: | Chris Henneghan |
Phone: | 610-269-2100 x237 |
E-mail: | chenneghan@schubert.com |
Web: | www.idtdna.com |
Integrated DNA Technologies, Inc. (IDT) is the largest supplier of custom nucleic acids in the U.S., serving the areas of academic research, biotechnology, clinical diagnostics and pharmaceutical development. IDT's primary business is the manufacturing of custom DNA and RNA oligonucleotides (oligos) for research applications. | |
 | |
With more than 400 employees, IDT synthesizes and ships an average of 36,000 custom oligos per day and has more than 77,000 customers worldwide. | |
 | |
IDT is headquartered in Coralville, Iowa, has a production center in San Diego, California and recently acquired Belgian manufacturer RNA-TEC. | |
 | |
The company plans to open its third facility later this year in Leuven, Belgium. | |
 | |
 | |
Company: | IKERCHEM LTD |
Booth: | 1085 |
Phone: | (34) 943 015381 |
E-mail: | ikerchem@ikerchem.com |
Web: | www.ikerchem.com |
IkerChem LTD with a wide expertise on the fields of cycloadditions, microwave-assisted organic synthesis and computational chemistry offers the best solutions in your design, synthesis or R&D projects. | |
 | |
IkerChem has confidential collaboration agreements with highly specialized laboratories to provide support and services in the following areas: | |
"¢Contract R&D | |
"¢Custom synthesis | |
"¢Computation Service | |
 | |
 | |
Company: | Image Reading Center |
Booth: | 1833 |
Media Contact: | Mark Punyanitya |
Phone: | 212-523-2487 |
E-mail: | Bio2007@imagereadingcenter.com |
Web: | www.imagereadingcenter.com |
The Image Reading Center is one of the premier Imaging Core Laboratories in the world, specializing in the advanced analysis of MRI, DXA, and CT scans for body composition assessment. The IRC utilizes high-resolution imaging for whole body (muscle, fat) and organ specific protocols (cardiac, brain, liver, kidney, spleen, and pancreas). Study design and conduct, site training and oversight, data management and quality control services are available for Phase I/II/III, national and international multi-center studies. | |
 | |
 | |
Company: | ImmigrationOptions.com - Savitz Law Offices, P.C. |
Booth: | 1969 |
Media Contact: | Bennett Savitz |
Phone: | 617-723-7111 |
E-mail: | Bsavitz@ImmigrationOptions.com |
Web: | www.ImmigrationOptions.com |
Savitz Law Offices, P.C. (www.ImmigrationOptions.com) provides legal services and expertise in all areas of immigration law both for corporate clients and individuals. In addition to obtaining temporary visas and permanent residence (Green Card) for foreign nationals, we help clients to file to become naturalized U.S. Citizens, and to solve specific problems with the Immigration Service or other government agencies. We have extensive experience working with the myriad of government entities involved in immigration matters, and have developed a worldwide network of contacts and other resources in order to assist our clients on any matter, from the routine to the extraordinary. | |
 | |
 | |
Company: | ImmunoGenetix Therapeutics, Inc. |
Booth: | 2619 (Kansas Pavilion) |
Media Contact: | Jim Laufenberg |
Phone: | 888.744.9246 |
E-mail: | jbl@igxbio.com |
Web: | www.ImmunoGenetix.com |
ImmunoGenetix Therapeutics, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection. The Company's lead product candidate, GenePro, is a DNA therapeutic vaccine incorporating a proprietary DNA construct that yields high levels of gene expression and non-infectious HIV protein production. GenePro induces a robust antibody and cellular immune response in animal models, without protein or viral vector boosts. | |
 | |
 | |
Company: | Indy Partnership, The |
Booth: | 1555 |
Media Contact: | Todd McCall |
Phone: | 317-965-7989 |
E-mail: | tmccall@indypartnership.com |
Web: | http://www.indypartnership.com |
The Indy Partnership is a regional economic development organization charged with spurring capital investment and job growth. Our staff aggressively markets the region to bring in new businesses, investments and jobs. We serve as a regional point-of-contact for responding to business development inquiries and generating good sales leads. | |
 | |
Recent Life Science success: | |
--Oxford BioSignals have announced plans to move their global headquarters to Carmel, Indiana | |
--Beckman Coulter announced that they will be moving a centrifuge operation to central Indiana | |
--Indianapolis MSA ranks # 9 in total biosciences employment - Biotechnology Industry Organization and Battelle Memorial Institute 2007. | |
 | |
 | |
Company: | Informa Healthcare |
Booth: | 1813 |
Media Contact: | Vanessa.cheung@informa.com |
Phone: | 44 20 7017 6980 |
E-mail: | Vanessa.cheung@informa.com |
Web: | www.informahealthcare.com |
Informa Healthcare serves the commercial needs of business leaders, the research needs of the scientific and academic communities and the "good practice" needs of healthcare professionals. As the most dynamic new publishing group serving the life science and medical markets, we offer a unique range of publishing formats, from major online databases and news services to research and review journals and books. | |
 | |
Exhibiting at BIO 2007 this year are Scrip Publishing, PharmaProjects, BioTechniques and Expert Opinion. Visit our booth 1813 for your FREE samples and demos or to speak to one of our representatives. | |
 | |
 | |
Company: | Innovive Inc |
Booth: | 3034 |
Media Contact: | Jim Fallon |
Phone: | 858 309 6631 |
E-mail: | jim@innoviveinc.com |
Web: | www.disposablecages.com |
Bring your animal work in house with the Innovive® System, the first fully disposable, irradiated rodent caging solution. Imagine a Turnkey Vivarium: No Washing, No Autoclaving, No Bottle Filling. | |
 | |
By eliminating cage washing and sterilization the Innovive® System simplifies vivarium operations, eliminates capital equipment requirements, and significantly reduces animal housing costs. | |
 | |
The Innovive® System is a state of the art, modularized, ventilated racking system that can be located anywhere in your facility without the need for a wash room. Your researchers will appreciate having access to their animals when and where they need them. WWW.DISPOSABLECAGES.COM | |
 | |
 | |
Company: | Inspire Pharmaceuticals |
Booth: | NC Pavilion |
Ticker Symbol & Exchange: | Nasdaq: ISPH |
Media Contact: | Jenny Kobin |
Phone: | 919-287-1219 |
E-mail: | jkobin@inspirepharm.com |
Web: | www.inspirepharm.com |
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. | |
 | |
Inspire employs a U.S. sales force for the promotion of AzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. | |
 | |
 | |
Company: | Institute of Cancer Research, The |
Booth: | 1864 |
Media Contact: | Jennifer Hodgson |
Phone: | 020 7153 5532 |
E-mail: | jhodgson@icr.ac.uk |
Web: | www.icr.ac.uk |
The Institute of Cancer Research works in a unique partnership with The Royal Marsden NHS Foundation Trust (the world's oldest cancer hospital) to form Europe's leading and largest comprehensive cancer centre. The joint research strategy and day to day interactions between researchers and clinicians ensure that discoveries made in The Institute's laboratories are swiftly translated into treatment and care for those affected by cancer. The Enterprise Unit has a range of collaboration and out licensing opportunities to offer interested parties, please call by the London Universities stand at BIO for more information. | |
 | |
 | |
Company: | Institute of Gene and Brain Science |
Booth: | Japan Pavilion 2549 / a9 |
Media Contact: | Hirotsugu Watabe |
Phone: | 81(3)5746-1333 |
E-mail: | info@ins-gbs.co.jp |
Web: | http://www.ins-gbs.co.jp/en/index.html |
The Institute of Gene and Brain Science is a drug discovery venture company. | |
 | |
We are developing innovative drugs and therapeutic techniques for two disease areas (to refer the followings) based on the research and medical findings of the central nervous system and brain tumors obtained by Dr. Masahiro Toda, a neurosurgeon, in addition to the basic medical findings in the field of immunology. | |
--Regeneration of central nervous system for central nerve damage and disease (spinal cord injury, cerebral infarction etc.) | |
--Cancer immune therapy | |
 | |
 | |
Company: | Integrated Project Management Company, Inc. |
Booth: | Massachusetts Pavillion, Booth 533, Stand D25 |
Media Contact: | Claudia Kovitz, CRK Communications LLC |
Phone: | 847-328-8119 |
E-mail: | crkovitz@sbcglobal.net |
Web: | www.ipmcinc.com |
"Project management" doesn't sound sexy, but it's fast becoming a key competitive strategy in the biopharmaceutical industry, helping companies perform more efficiently and effectively. Illustrating this trend: Integrated Project Management Company, a leading provider of professional project management services to the life sciences industry, has quadrupled its biotech and pharmaceutical clientele in less than five years, with the pace ever-quickening. IPM vice president Tim Noffke has become a thought-leader on such topics as streamlining product development (his team helped one global company cut time-to-market in half), sound alliance management and creative problem-solving. | |
 | |
 | |
Company: | INTERES Invest in Spain |
Booth: | 979 |
Phone: | 34 91 503 5800 |
E-mail: | interes@interes.org |
Web: | www.investinspain.org |
SPAIN: FOR BIOTECHNOLOGY. | |
--The Spanish biotechnology sector is growing four times faster than the EU-15 average. | |
--Multinational companies such as GSK, Lilly, Merk Serono o MSD have RD and production centers in Spain. | |
--Increasing public and private investment and efficient technology transfer. | |
 | |
INTERES Invest in Spain is the leading government organization that supports foreign enterprises seeking to set up or expand their business in Spain. We offer comprehensive, efficient and confidential consultation at no cost during all stages of the investment process. Visit our stand at BIO: Your first port of call for investing in Spain. | |
 | |
 | |
Company: | inVentiv Health |
Booth: | 1220 |
Ticker Symbol & Exchange: | VTIV |
Media Contact: | Felicia Vonella |
Phone: | 212.308.7155 |
E-mail: | fvonella@inventivhealth.com |
Web: | www.inventivhealth.com |
inVentiv Health (NASDAQ: VTIV) is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its three core business segments: inVentiv Clinical, inVentiv Communications and inVentiv Commercial. inVentiv Health currently works with over 200 unique pharmaceutical, biotech and life sciences clients, including all top 20 global pharmaceutical companies. For more information, visit www.inventivhealth.com. | |
 | |
 | |
Company: | Invest in Germany |
Media Contact: | henkel@invest-in-germany.com |
Phone: | (617) 401 2120 |
E-mail: | hermann@iic.de |
Web: | www.invest-in-germany.com |
Invest-in-Germany (IiG) is the German federal investment promotion agency which informs, assists and consults foreign investors pursuing business opportunities in Germany. IiG provides full service support in the implementation of investment decisions, including comprehensive market analysis, specific information on business costs, and professional guidance with site analysis. Companies planning to establish or expand business operations in Germany can obtain detailed information on tax regulations, regional and federal financial support, and other aspects of the German corporate environment. IiG's services are free of charge. | |
 | |
Contact US: Palo Alto, Chicago, Washington and new in Boston: 1 Broadway Cambridge MA 02142, Phone: 6174012120. | |
 | |
 | |
Company: | Invitrogen |
Booth: | 239 |
Ticker Symbol & Exchange: | IVGN |
Media Contact: | Eric Endicott |
Phone: | 760-268-7438 |
E-mail: | eric.endicott@invitrogen.com |
Web: | www.invitrogen.com |
Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company is celebrating 20 years of accelerating scientific discovery. Invitrogen globally employs approximately 4,300 scientists and other professionals and had revenues of more than $1.15 billion in 2006. | |
 | |
 | |
Company: | Iowa Department of Economic Development |
Booth: | Iowa Pavilion (1340 - 1361) |
Media Contact: | Kay Snyder, Communications Manager - Nickelle Stevens, The Integer Group |
Phone: | 515-360-2209 / 515-710-2618 |
E-mail: | nstevens@integermidwest.com |
Web: | www.iowalifechanging.com |
Iowa offers the ideal expansion solution for bioscience companies. For investors looking to create beneficial public/private partnerships, Iowa is the smart choice. And for 1,800 bioscience establishments, Iowa is already an exciting place to do business. The state is home to three public universities that are world renowned for their life sciences research. Iowa leads the nation in the production of renewable energy and raw biomass. A competitive economic development incentives program and the opportunity to achieve a balanced personal life are just a few reasons to take a closer look at Iowa. Stop by the Iowa Pavilion, or visit www.iowalifechanging.com to learn more. | |
 | |
 | |
Company: | IPS Research Company |
Booth: | 2233 |
Media Contact: | Fred Lee |
Phone: | 405-235 8188 |
E-mail: | flee@ipsresearch.com |
Web: | www.ipsresearch.com |
At IPS Research Company we strive to collect the highest quality data through consistent good clinical practice. We are proud of our proven ability to recruit, enroll and retain patients for our clients. | |
 | |
We are continually looking for better ways to serve our clients. With over 50 years combined research experience, our team of clinicians takes pride in the services we provide. | |
 | |
At IPS Research Company we strive to build a partnership with our pharmaceutical clients and our patients to achieve the finest clinical trial performance. | |
 | |
 | |
Company: | Isotechnika Inc. |
Booth: | 720 |
Ticker Symbol & Exchange: | TSX:ISA |
Media Contact: | Stephanie Gillis-Paulgaard |
Phone: | (780) 487 1600 |
E-mail: | sgillis-paulgaard@isotechnika.com |
Web: | www.isotechnika.com |
Isotechnika Inc. is a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Isotechnika's lead compound is ISA247, a new calcineurin inhibitor with a different metabolic profile than cyclosporine. ISA247 has completed a Canadian Phase 3 trial and commenced a European/Canadian Phase 3 trial for the treatment of moderate to severe psoriasis. A Phase 2b trial using ISA247 for the prevention of kidney graft rejection has also commenced in North America. Additionally, Isotechnika has developed TAFA93, a novel prodrug of the mTOR inhibitor rapamycin. TAFA93 has successfully completed Phase 1 trials. | |
 | |
 | |
 | |
Company: | ISTO Technologies, Inc. |
Media Contact: | Mitchell Seyedin Ph.D. |
Phone: | 314-995-6049 |
E-mail: | 314-995-6025 |
Web: | www.istotech.com |
ISTO Technologies, Inc, St. Louis, Missouri, is a clinical stage orthobiologic company focused on developing differentiated products for sports medicine and spinal therapy. ISTO's products in development are intended for repair and regeneration of bone and cartilage tissues in knee joints and spine. ISTO's lead cartilage product in phase I/II clinical trials is DeNovo-ET® in partnership with Zimmer, Inc. DeNovo- Et is a living tissue-engineered graft for the restoration of cartilage defects in the knee. Also under development are: NuQu injectable juvenile cartilage cells for spinal disc repair; and InQu a tissue-engineered scaffold for bone and other soft tissue repair. | |
 | |
 | |
Company: | Iter srl |
Booth: | 2025 Italy Pavillon |
Media Contact: | Domenico Piazza |
Phone: | 39 02 2831161 |
E-mail: | bioforum@iter.it |
Web: | www.iter.it/en |
Starting from 2004 bioforum is the meeting between science and business in Italy. Visit the web site www.bioforum.it/en, look the masterplan www.bioforum.it/2006/english/conference.htm , the committee www.bioforum.it/2006/english/committee.htm, previous editions www.bioforum.it/english/previous.htm. | |
 | |
Since 1989 ITER creates tailoring services for the scientific and business world. ITER organizes successful Seminars, Congresses and Exhibitions on innovative topics, such as biotechnologies, nanotechnologies, computer science and communication by using a rich and updated database. | |
 | |
ITER edits specialized publication concerning the ICT world dedicated to the professional field, and publishes services by writing and printing specialized contents: research, handbooks, books and brochure, even in limited edition. | |
 | |
 | |
Company: | Japan External Trade Organization (JETRO) |
Booth: | 2549 |
Media Contact: | Taku Sato |
Phone: | (212)-997-0400 |
E-mail: | Taku_Sato@jetro.go.jp |
Web: | http://www.jetro.org/ |
Japan External Trade Organization (JETRO) has organized a Japan Pavilion, consisting of 32 Japanese biotech companies, at BIO 2007. We are also offering one-on-one meetings with these companies, to facilitate future international partnerships and collaborations. | |
In addition, we have organized two seminars at BIO 2007: | |
--"Agricultural R&D in Biomass Conversion for Renewable Energy," | |
--"Partnering with Japanese Biotech," which will focus on new opportunities for partnerships. | |
 | |
These seminars will provide in-depth look at current state of Japanese biotech industry. | |
 | |
For more information on Japan Pavilion participants, and JETRO's activities at BIO 2007, please check: http://www.jetro.org/bio2007. | |
 | |
 | |
Company: | J. Calnan & Associates, Inc. |
Booth: | #533/A19 |
Media Contact: | Michelle Elchaak |
Phone: | 617-801-0252 |
E-mail: | melchaak@jcalnan.com |
Web: | www.jcalnan.com |
J. Calnan & Associates, Inc. (JC&A), headquartered in Quincy, MA with an office in NYC, is one of New England's leading construction management firms specializing in world-class pre-construction consulting, project management, facilities maintenance, and construction projects in the life science industry. JC&A has excelled at working in challenging GMP environments including occupied spaces, challenging user groups, and strict security requirements and demanding schedules. Our team will ensure that the critical issues regarding material selection and availability, quality assurance, safety, security and milestones are understood. | |
 | |
Our clients include Wyeth Pharmaceuticals, Acceleron Pharma, Draper Laboratory, Parexel and Millipore Corporation. Visit website: www.jcalnan.com. | |
 | |
 | |
Company: | Joulé Scientific Staffing Solutions |
Booth: | 1967 |
Media Contact: | Mary Jane Martin |
Phone: | 800-382-0382 x418 |
E-mail: | mjmartin@jouleinc.com |
Web: | www.joulescientific.com |
For over a decade, Joulé has defined the market for Scientific Staffing. Joulé Scientific delivers the best solution for each biotechnology, pharmaceutical, chemical, and clinical research organization. Joulé has developed the perfect process for finding that perfect employee. From the discovery phase to strategy and planning, through execution and onto results, there is a single mission - providing the perfect employee. Our systematic yet customizable method relies heavily on the experience of trained professionals and technology based tools. This market-defining process and service not only provides positive results today, but anticipates our clients' needs for tomorrow. The Right Match is in Our DNA. www.joulescientific.com | |
 | |
 | |
Company: | Journal of BIOLaw & Business, The |
Booth: | Massachusetts Pavillion #533/C5 |
Media Contact: | Robin JR Blatt |
Phone: | 617.633.5522 |
E-mail: | editor@biolawbusiness.com |
Web: | www.biolawbusiness.com |
THE JOURNAL OF BIOLAW & BUSINESS (JB&B) is the leading international publication focused on critical topics in 21st century life sciences law, business, regulatory and policy matters. It's reading for those who want to stay ahead of the curve. | |
 | |
Established in 1997 and published quarterly, the The JB&B Collection also consists of thematic BioLaw & Business Supplements and JB&B International Series with country-specific supplements. On-line access, electronic updates, notification of events are available through JB&B News Service. | |
 | |
From emerging business models or regulatory and legal trends...to debates and advances in stem cells, biogenerics, pricing policies, genomics and pharmaceutical research... JB&B reports on it all. JB&B contributing editors, advisors and authors are world experts, providing original analysis and tools for life science executives | |
 | |
Visit www.biolawbusiness.com for subscriptions, editorial, advertising or contact orders_biolaw@fulcoinc.com or JB&B Customer Service at 1.888.732.6732. | |
 | |
 | |
Company: | JTC Corporation |
Booth: | 2533 - Singapore Pavilion |
Media Contact: | Ms Carin Leong |
Phone: | 65 68833062 |
E-mail: | leongwwc@jtc.gov.sg |
Web: | www.jtc.gov.sg; www.one-north.com |
JTC Corporation (JTC) is the lead agency in Singapore to develop key industrial facilities and vibrant industrial space. Currently, JTC has under its management many developments including four wafer fab parks and an advanced display park, two business parks, a chemicals hub at Jurong Island, as well as logistics hubs for aerospace, chemical and general warehousing industries. | |
 | |
Catering to the biomedical sciences industry, JTC has developed the Biopolis, a 185,000 sqm, seven-building research complex, which is a hotspot for biomedical research talent, and the Tuas Biomedical Park, a premier manufacturing hub with key infrastructure provisions for biomedical companies. | |
 | |
 | |
Company: | KBI BioPharma, Inc. |
Booth: | 2373 |
Phone: | (919) 479-9898 |
E-mail: | marketing@kbibiopharma.com |
Web: | www.kbibiopharma.com |
KBI Biopharma, a leader in contract biopharmaceutical development, enhances drug value by partnering with our clients to develop products more rapidly and efficiently. | |
 | |
We develop scalable, robust processes which result in stable, active products. Our clients benefit from faster time to market and lower cost of manufactured goods. | |
 | |
Our innovative team has a broad range of product development and proven problem-solving experience, with an emphasis in formulation and analytical development. We are known for our unique application of biophysical and biochemical protein characterization and our collaborative approach, our emphasis on close communication and our ability to accelerate milestone target dates. | |
 | |
 | |
Company: | KenkouKagakuKenkyu-kai.Co,.Ltd. |
Booth: | 2549 B-2 |
Media Contact: | Takeno Dan |
Phone: | 81-774-32-6282 |
E-mail: | info@kekkan-bijin.jp |
Web: | http://www.kekkan-bijin.jp |
KenkouKagakuKenkyu-kai.Co,.Ltd. (http://www.kekkan-bijin.jp/)is a health science research company focused in health check machine of Video Microscope "Kekkanbijin". | |
 | |
Kekkanbijin can tell blood flow conditions at a glance without drawing blood. Observation of the status of blood capillary shape and cleanliness of tissue fluid is useful as a means to measure health. It also finds application in the field of health products as a sales tool providing realistic before and after comparisons. | |
 | |
 | |
Company: | Kentucky Cabinet for Economic Development |
Booth: | 1907 |
Media Contact: | Paul Boisvert |
Phone: | 502-564-4300 x3223 |
E-mail: | Paul.Boisvert@ky.gov |
Web: | www.ThinkKentucky.com/dci |
The Kentucky Economic Development Cabinet and several of Kentucky's leading biotech start-up companies will be at BIO 2007 in Booth 1907. Experts will be on hand to talk about shovel-ready development sites, workforce training, incentive programs, community profiles, small business assistance and other resources. For high-techs looking to locate or relocate their companies, we are the only state to specifically match both federal Phase 1 and Phase 2 SBIR-STTR awards. We're already matching federal Phase 1 awards made after January 1, 2006, and will start matching Phase 2 awards beginning July 1, 2007. More information is available at www.ThinkKentucky.com/dci | |
 | |
 | |
Company: | KeyGene Science Co Ltd |
Booth: | 2341 |
Phone: | 82-11-90142389 |
E-mail: | jinwoo@catholic.ac.kr |
Web: | www.keygene.co.kr |
KeyGene Science is developing new Diagnostic Cancer Biomarkers that make early detection of cancers possible by an investigational blood test in a simple, convenient and economic way. Simple blood test can be a useful tool of mass screening for cancers. | |
 | |
HepaCheck, a new diagnostic sandwich ELISA kit, can identify liver cancer with an accuracy of greater than 80% through estimating a protein in serum by use of antibodies obtained from oncogene HCCR. | |
 | |
Other novel biomarkers against Leukemia, Thyroid cancer, Colon cancer, Breast cancer, Cervical Cancer and Lung Cancer possessing potential diagnostic capability at laboratory tests are under process of validation. | |
 | |
Patent is registered in Japan, Korea, U.S.A. and pending in some countries. This will protect HepaCheck and other potential diagnostics from duplication by competitors. Marketing strategies are partnering by regional licensing contract. | |
 | |
 | |
Company: | KeyNeurotek Pharmaceuticals AG |
Booth: | 575 |
Media Contact: | Dr. Frank Striggow |
Phone: | 49 391 6117220 |
E-mail: | info@keyneurotek.de |
Web: | www.keyneurotek.de |
KeyNeurotek is localized in Magdeburg, Germany, one of the leading centres of neuroscience in Europe. KeyNeurotek pursues a number of drug candidates in various preclinical and clinical stages. The most advanced compound, KN38-7271, a cannabinoid receptor agonist, is in Phase IIa in comatose patients with traumatic brain injury. The company has unique functional and tissue-based high throughput screening platforms for compatible ex vivo and in vivo studies (TELOMICSTM). Based on its know-how, KeyNeurotek develops innovative therapies for the treatment of various neurodegenerative diseases of the central nervous system, such as traumatic brain injury (TBI), stroke, and Alzheimer's disease. | |
 | |
 | |
Company: | KGK Synergize Inc. |
Booth: | 507 Ontario Pavilion |
Media Contact: | Kristen Reynolds, Associate Director, Marketing & Sales |
Phone: | 519-438-9374 Ext. 222 |
E-mail: | Reynolds@kgksynergize.com |
Web: | www.kgksynergize.com |
KGK Synergize Inc. is a Canadian biotechnology company having two divisions; 1) a fast growing contract research organization (CRO) for third parties 2) a new product development (NPD) division. | |
 | |
Both ISO 9001:2000 and GLP certified, the CRO division offers a wide range of in-house research services to the client including analytical testing, cell screening, toxicity studies, in vivo models and human clinical trials. | |
 | |
The NPD division develops nutraceutical and functional food products to the point where they are ready to manufacture and market. Currently, products are in the areas of cardiovascular, type II diabetes, inflammation and anti-cancer. | |
 | |
 | |
Company: | Kingmed Diag |
Booth: | 1633, 1637 |
Media Contact: | Joyce Deng |
Phone: | 86 20 22283222 ext. 320 |
E-mail: | joycedeng@kingmed.com.cn |
Web: | www.kingmed.com.cn |
Kingmed is the largest and the first clinical laboratory that is operated with international standard (ISO17025 & CAP) in China and is the first medical institute that won "Quality award" in China | |
 | |
Kingmed's core Services include: | |
--Clinical laboratory testing: the nation's leading provider of clinical laboratory testing, information and services in China. Now have 1000 test items. | |
--Clinical trials: to be the central laboratory for phase I through phase IV clinical trials that serves internationally | |
--Physical examination: expertise for annual check-up, about 20000 persons/ year. | |
--Food and hygiene testing: to help consumer goods industries to develop, implement and evaluate the safety and quality of operation process | |
 | |
 | |
Company: | Knobbe Martens Olson & Bear |
Booth: | 1469 |
Media Contact: | Sara McKibben (Director of Business Development) |
Phone: | 949-760-0404 |
E-mail: | Sara.mckibben@kmob.com |
Web: | www.kmob.com |
Knobbe Martens represents clients in all areas of intellectual property law and litigation. Clients include public and private companies at various stages of growth, from start-up to the Fortune 500 worldwide. Founded in 1962, the firm is one of the largest intellectual property law firms in the United States with over 180 lawyers firm wide. Knobbe Martens has been recognized in surveys for excellence in all aspects of intellectual property law. In 2007, the firm was ranked #1 for growth in patent litigation and in the top 10 for number of patent litigation cases in a nationwide survey conducted by IP Law 360. In addition, several members of the firm have been voted among the world's leading intellectual property lawyers. www.kmob.com | |
 | |
 | |
Company: | Krakow Lifescience Park - Jagellionian Center of Innovation Ltd POLAND |
Booth: | 1654 |
Media Contact: | Lisette Mermod (London) |
Phone: | 44 7968 970 942 / 48 50 600 6620 |
E-mail: | Pawel.blachno@jci.pl (Poland) |
Web: | www.jci.pl |
Pharmaceutical companies from all over the world invest in Krakow attracted by local economic strengths and a rich cultural environment. With its R&D potential, Krakow is steadily becoming Poland's lifescience leader. Supported by the Lifescience Cluster the JCI Ltd seeks to: | |
 | |
"¢become the single point of contact for biobusiness relationship development and progressing business and scientific collaborations, | |
"¢promote Poland's first-to-market biobusiness property offer to a global market | |
"¢facilitate introductions to Krakow's organisations | |
 | |
For preliminary information regarding the benefits and opportunities for direct development and investment in Krakow's special economic zones please contact Mr Pawel Blachno at pawel.blachno@jci.pl | |
 | |
 | |
Company: | Kringle Pharma, Inc. |
Booth: | 2549 |
Media Contact: | Kei Nakanishi, Manager, Business Development |
Phone: | 81-6-6831-3330 |
E-mail: | info@kringle-pharma.com |
Web: | www.kringle-pharma.com |
Kringle Pharma, Inc. is a venture biopharmaceutical company established in 2001. Our corporate mission is to provide solution for unmet medical needs by developing cutting edge medical treatment for patients suffering from cancer or incurable diseases through clinical development of Hepatocyte Growth Factor (HGF) and NK4. To achieve its goal, Kringle is now undertaking two R&D projects; 1) clinical development of recombinant human HGF protein for repair and regenerative therapy and 2) clinical development of NK4 protein/gene as a novel cancer treatment. Kringle is seeking to conclude a strategic alliance with pharmaceutical companies that is interested in innovative medical seeds. | |
 | |
 | |
Company: | LabScores |
Booth: | 2633 |
Media Contact: | PC Sijmons |
Phone: | 31-653-246-095 |
E-mail: | info@labscores.com |
Web: | www.labscores.com |
LabScores® relational databases can contain almost any data you need to store in your biotech company and spans CRM-HRM-LIMS-GMP functionalities all into one seamless application. LabsScores is available in modules that fit your requirements at any stage of your company. LabScores runs on FileMaker® Pro software, one of the worlds most reliable database platforms available and can be accessed by up to 250 concurrent client computers. The modules are unlocked, allowing users to implement changes in a dynamic business and research environment quickly and at low cost, taking advantage of the user-friendly FileMaker programming capabilities. | |
 | |
 | |
Company: | Lehigh Valley Economic Development Corporation |
Booth: | 001440 |
Media Contact: | Joe McDermott |
Phone: | 610-266-6775 |
E-mail: | lvedc@lehighvalley.org |
Web: | www.lehighvalley.org |
Lehigh Valley Economic Development Corporation (LVEDC), is a one-stop, full-service business and economic development agency. Coordinating with state, county, and municipal governments, chambers of commerce, industry organizations, educational institutions and utilities, the award-winning LVEDC streamlines the relocation and expansion process for businesses. LVEDC also administers the Southside Bethlehem KIZ. The KIZ program is a key element of Governor Rendell's economic stimulus package. By focusing talent and resources, KIZs build synergies among emerging technology companies. Entrepreneurs find ready resources for workforce and financial assistance. The KIZ program seeks to reverse the brain drain of talented students and entrepreneurs. | |
 | |
 | |
Company: | LentiKats |
Web: | www.lentikats.eu |
"Lentikats" is a technology focused on the development and implementation of immobilized cells and enzymes. This technology is based on the immobilization of biomass or enzymes into a polyvinylalcohol carrier. Our main goal is the global implementation of Lentikats Biotechnology in fermentation, biotransformations and bioconversions processes. This primarily concerns the development, production and application of Lentikats Biocatalysts for industrial applications in distillery (bioethanol production), waste water treatment (pollutants biodegradations), pharmaceutics and food industry (robust biocatalysts production). | |
 | |
 | |
Company: | Limerick NeuroSciences, Inc. |
Media Contact: | Debra Bannister |
Phone: | 530 676-8001 |
E-mail: | media@limerickneuro.com |
Web: | www.limerickneuro.com |
Limerick NeuroSciences, Inc. is a venture-funded biopharmaceutical company focused on the development of safe and potent pharmaceuticals with attenuated neurotoxicity. The company was founded by the scientific team of Franz Hefti, Ph.D., Leslie Benet, Ph.D., Ving Lee, Ph.D., Cynthia McCormick, M.D., and Wendye R. Robbins, M.D. Limerick began operations 2006, with venture funding from Arch Venture Partners, Sevin Rosen Funds, and Altitude Life Science Partners, as well as others. Limerick's first clinical compound successfully completed an exploratory clinical trial and is continuing development. Dr. Ving Lee, will represent the company during BIO's 2007 Business Forum on Wednesday morning, May 9. | |
 | |
 | |
Company: | Locus Pharmaceuticals, Inc. |
Media Contact: | Robert Dickey IV |
Phone: | 215-358-2006 |
E-mail: | rdickey@locuspharma.com |
Web: | www.locuspharma.com |
Locus is a world leader in computational drug design. The Company's core technology is a fragment-based, computational approach, which Locus has combined with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform. Locus is using its capabilities to develop its own compounds and has also entered into drug design/development collaborations with pharmaceutical partners. All of the Company's internal development programs emanate from its computational technology and are focused on oral drug therapies, principally in cancer and inflammation. | |
 | |
 | |
Company: | MacroChem Corporation |
Booth: | 533/A15 |
Ticker Symbol & Exchange: | OTCBB: MACM.OB |
Media Contact: | Jordan Silverstein, The Investor Relations Group |
Phone: | 212-825-3210 |
E-mail: | info@macrochem.com |
Web: | www.macrochem.com |
MacroChem (OTCBB: MACM.OB) is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Currently, our portfolio of proprietary product candidates is based on our drug delivery technologies: SEPA®, MacroDerm(TM), and DermaPass(TM). Our patented SEPA topical drug delivery technology (SEPA is an acronym for "Soft Enhancement of Percutaneous Absorption," where "soft" refers to the reversibility of the skin effect of the technology, and "percutaneous" means "through the skin") enhances the efficiency and rate of diffusion of drugs into and through the skin. | |
 | |
 | |
Company: | Magnisense |
Booth: | 1307 - France Pavilion |
Media Contact: | Luc Lenglet |
Phone: | 33 (0)6 10 92 02 24 |
E-mail: | contact@magnisense.com |
Web: | www.magnisense.com |
Magnisense develops and markets a new generation of immunoassays for human and animal diagnostics, food safety and environmental protection. These innovative immunoassays are based on magnetic bead markers, which deliver the accuracy of laboratory testing with the ease of use of rapid test methods currently on the market. | |
 | |
Magnisense is developing two application areas: | |
 | |
MIAstrip: Point of care testing with a single dose, producing objective, quantifiable and traceable results via a portable reader for cardiac, tetanus, microbial or viral infection markers among others. | |
 | |
MIAflo: Disposable cartridges for detection of bacterial contamination in food products, e.g. Listeria and Salmonella, or in water, e.g. Legionella, with a sensitivity that brings a significant reduction in testing time. | |
 | |
 | |
Company: | Miami-Dade Beacon Council, The |
Booth: | 1743 |
Media Contact: | Xavier Gonzalez |
Phone: | 305-579-1341 |
E-mail: | xgonzalez@beaconcouncil.com |
Web: | www.beaconcouncil.com |
The Beacon Council, Miami-Dade County's official economic development partnership, is a not-for-profit, public-private organization that focuses on job creation and economic growth. | |
 | |
The Beacon Council works to keep Miami-Dade, which is home to world-class life science research institutions and life science companies, in the forefront of today's life science industry. | |
 | |
The Beacon Council's free and confidential services include Market Research and Demographics Information; Business Costs Information; Site Selection Assistance; Permitting Facilitation; and Access to Labor Training and Financial and Incentive Programs. | |
 | |
 | |
Company: | Malaysian Biotechnology Corporation Sdn Bhd |
Booth: | 170 - Malaysia Pavilion |
Media Contact: | Norashikin Abdullah Shan |
Phone: | 603-2116 5588 / 6017-226 3411 |
E-mail: | norashikin.as@biotechcorp.com.my |
Web: | www.biotechcorp.com.my |
BiotechCorp is the implementation agency leading the development of the biotechnology industry in Malaysia. Our focus areas are healthcare, agriculture and industrial biotechnology. Malaysia has a unique set of value propositions conducive to biotechnology development and we seek investment, collaboration, partnerships and R&D opportunities. | |
 | |
 | |
Company: | Marks & Clerk |
Booth: | 1774 |
Media Contact: | Alan Ritchie |
Phone: | 44 (0) 779 565 1712 OR 44 (0) 207 420 103 |
E-mail: | aritchie@marks-clerk.com |
Web: | www.marks-clerk.com |
Marks & Clerk is one of the world's leading firms of patent and trade mark attorneys. We also have an associated intellectual property law firm, Marks & Clerk Solicitors. Our highly experienced bioscience professionals provide strategic guidance on intellectual property across all disciplines to clients worldwide. The members of our Bioscience Group all have relevant technical backgrounds, and in many cases, a higher qualification in specialist areas such as molecular biology, pharmaceuticals, genomics, immunology, cell biology, structural biology, veterinary science, virology, stem cells, diagnostics, proteomics, bioinformatics, vaccines, nanotechnology, medical devices and plant variety protection. | |
 | |
 | |
Company: | Massachusetts Biotechnology Council (MBC) |
Booth: | 533 - Massachusetts Pavilion |
Media Contact: | John Lacey, Director of Communications |
Phone: | 617-674-5143 |
E-mail: | John.lacey@massbio.org |
Web: | www.massbio.org |
The Massachusetts Biotechnology Council (MBC), founded in 1985, is a not-for-profit trade organization that provides services and support for the Massachusetts biotechnology industry. The MBC is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 500 companies, academic institutions and service organizations involved in life sciences, the MBC works with public leaders to advance policy and promote education, while providing programs for its members. |
Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.
Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow@businesswire.com.